Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

HISTORICAL FACTS: 4 - The Untold Story

How to recall an email message on Outlook and Gmail

Microsoft and Google both allow users to unsend emails in just a few simple steps

Manchester Evening News

Would You Prefer to Get Each of Our Posts as an E-Mail?

There are already two ways of getting our posts in your mailbox: To get the Volokh Daily e-mail, go to https://reason.com/volokh/e-mail-delivery/, enter your e-mail address, and then click on the link in the verification e-mail that you get. To get each post in your Outlook mailbox as it appears: In…

Reason

Microsoft Teams and Outlook down for thousands of users

There were also issues reported with Microsoft 365 and the Microsoft store

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

FEC Finds Google Isn't Deliberately Biased Against Republicans

Plus: DEI trainings don't work, a case for compensating organ donors, and more...

Reason

A ‘march to unite India’, led by Congress, reaches half-way mark

The nationwide march on foot, led by India’s main opposition leader Rahul Gandhi, has reached its 80th day.

Al Jazeera

Morning Show Ep 3: Will BJP’s freebies win them voters?

Atul and Manisha are joined by Ashwini Sharma, a former bureau chief at the Indian Express who is currently with Outlook, and Rajeev Khanna, associate editor with Citizen. They discuss BJP’s manifesto promises and compare them with what the Congress is offering.

Newslaundry

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Padmanand Jha is no more. And Indian journalism is the poorer for it

In his journalism as well as in life Padmanand Jha – Paddy to friends – was a fighter till the very end. He was also proof that a good journalist could be a sincere, honest, and sensitive human being as well.

Newslaundry

The week in audio: Lives Less Ordinary; Don’t Log Off; Lady Killers With Lucy Worsley

Ordinary people tell extraordinary stories, while Lucy Worsley examines a Victorian poisoning mystery

The Guardian - UK

Outlook poses tough questions for next steps on COVID-19 vaccines - Roll Call

Health care officials face tough questions as they set policy to deal with the next phase of the pandemic and try to get the messaging right.

Roll Call

‘Process is the punishment’: Neha Dixit on her 5-year legal battle over her Outlook reportage

It’s been over five years since a case was filed against independent journalist Neha Dixit for criminal defamation and promoting “disharmony, enmity, hatred or ill-will” through a five-part series she wrote for Outlook magazine in 2016.

Newslaundry

How to block email tracking and disable hidden read receipts

Your inbox is being spied on more often than you think by tiny, hidden tracking pixels. Take back control of your email by blocking them.

Input

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Bharatiya Janata Party

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.